Apotex: The Sherman Family, Generic Drugs, an Unsolved Murder and a 2026 IPO

Apotex is proof that a generics company can be built to national scale in a country whose drug-pricing rules were written for someone else. Barry Sherman turned patent litigation into a business model, fought Ottawa and the brand-name industry for forty years, and left behind a company with manufacturing capacity of 25 billion doses, about 800 products and sales in roughly 70 countries. His death and the subsequent sale to SK Capital ended the family era; the 2026 initial public offering opened a new one in which public investors, not the Shermans, will decide how much to spend on biosimilars, GLP-1 generics and acquisitions. This article explains how Apotex was built, what happened after 2017, what the IPO reveals about the business and how Canada’s drug-pricing regime shapes it. It is part of the Canada Company Stories hub.

How did Barry Sherman turn patent challenges into a business?

Sherman, an engineering PhD from MIT, founded Apotex in Toronto in 1974 after selling Empire Laboratories, a small drug maker he had inherited from an uncle. His insight was that Canada’s compulsory-licensing regime, which until 1993 allowed generic makers to copy patented drugs for a small royalty, could be combined with aggressive litigation to launch generics years before competitors.

When Canada abolished compulsory licensing to comply with trade agreements, Sherman adapted by making Apotex the most frequent litigant in Canadian pharmaceutical patent law. The company filed notices of allegation against brand patents as soon as the rules permitted, took cases to the Supreme Court of Canada, and sometimes launched at risk. In 2006 it put a generic of Sanofi and Bristol-Myers Squibb’s blood thinner Plavix on the US market before litigation ended, and in 2010 it launched generic Lipitor in Canada after a four-year fight with Pfizer. Not every case went Apotex’s way; the Supreme Court’s 2015 Sanofi-Aventis ruling on damages under Section 8 of the patent regulations, and large damages awards in other cases, were part of the cost of doing business.

By the 2010s Apotex was Canada’s largest generic manufacturer, with annual sales commonly reported at more than C$2.5 billion, more than 300 products and operations in over 115 countries, and Sherman had become one of the country’s richest people. The model also attracted regulatory trouble: US FDA warning letters at Toronto-area plants in 2009 and 2010, an import ban that lasted until 2011 and a ban on the company’s Bangalore plant in 2014 over data integrity.

What happened after the Sherman murders in December 2017?

Barry and Honey Sherman were found dead in their North York home on 15 December 2017, strangled, in what Toronto police later classified as a targeted double homicide. No arrests have been made, the family has offered a reward of C$35 million and the case remains open nearly nine years later. The couple’s estate, unsealed by the Supreme Court of Canada in 2021, became the subject of litigation among heirs and former associates, and Jonathan Sherman, Barry’s son, took a leading role in the family’s affairs.

The company itself was kept running by Jack Kay, Sherman’s long-time deputy, and by Jeremy Desai as chief executive until his departure in early 2018; Jeff Watson, an Apotex veteran, became president and chief executive later that year and still holds the job. The family’s priority, after the initial shock, was stability rather than a quick sale, and Apotex spent the years to 2022 settling legacy liabilities, including a US$24.1 million US Department of Justice fine in 2020 for price-fixing of generics and a US$49.1 million settlement with state attorneys general in October 2024.

In September 2022 the family agreed to sell Apotex to SK Capital Partners, a New York private-equity firm specialising in pharmaceuticals and chemicals, and the transaction closed on 3 April 2023; the price was not disclosed. SK Capital installed Allan Oberman as president and chief executive at closing, though Watson was again named chief executive by the time of the 2026 IPO. The sale closed the founder era and, in retrospect, began the preparation for the public listing three years later.

Why did SK Capital take Apotex public in 2026?

Private-equity owners take companies public to repay debt, create a currency for acquisitions and start an exit, and Apotex’s listing did all three. Apotex Health Corp’s shares began trading on the Toronto Stock Exchange on 10 June 2026 at C$24, in an upsized offering that raised about C$1.495 billion of gross proceeds in total, of which C$850 million was primary capital for the company. The company applied C$800 million to debt repayment, making C$825.7 million of term-loan repayments in the quarter.

The effect on the balance sheet was immediate. Net debt fell from C$2.88 billion at 31 March 2026 to C$2.17 billion at 30 June 2026, with total debt of C$2.43 billion and cash of C$258.8 million. Morningstar DBRS assigned an investment-grade issuer rating of BBB (low) in July 2026, the revolving credit facility was raised to C$1.2 billion and made unsecured, and in October 2026 Apotex closed a C$1.25 billion inaugural senior unsecured notes offering. The company also declared a first quarterly dividend of C$0.06 a share.

SK Capital began to monetise quickly. In September 2026 Apotex announced a bought-deal secondary offering, upsized from C$750 million to C$850 million, in which the selling shareholder reduced its stake. That sequence, IPO in June, secondary in September, bonds in October, is a textbook private-equity exit path and leaves Apotex with a broader shareholder base than it has had in its history. It also puts Apotex alongside Constellation Software among the few large Canadian companies to list in Toronto rather than New York.

What do the first public results say about the business?

Apotex’s first quarterly report as a listed company, for the three months to 30 June 2026 (the first quarter of its fiscal 2027), shows a business that is stable underneath a dramatic headline. Reported revenue fell 25.8 per cent to C$848 million because the prior-year quarter included C$307.8 million from a generic of Revlimid sold under a volume-limited licence; excluding that product, revenue rose about 2 per cent and adjusted EBITDA was flat at C$259 million, a 30.6 per cent margin. The company reported a net loss of C$38.3 million, caused mainly by C$72.8 million of share-option charges tied to the IPO; adjusted net income was C$142 million.

By geography, Canada is the largest and fastest-growing market, with revenue of C$412.7 million up 11.5 per cent, followed by the United States at C$362.9 million and international markets at C$72.4 million. By product line, conventional generics excluding the Revlimid product grew 16 per cent, specialty generics fell 18.5 per cent and brands and biosimilars rose 7.8 per cent to C$161 million. Guidance for fiscal 2027 is for upper-mid-single-digit revenue growth and an adjusted EBITDA margin of about 30 per cent.

Those margins are high for a generics company, reflecting Apotex’s position in its home market, where it is the leading supplier, and its vertical integration from active ingredient manufacturing through to distribution. The weak spot is the United States, where revenue excluding Revlimid fell 8.6 per cent amid the price erosion that has hurt every generic supplier there.

Where is Apotex looking for growth?

Apotex’s growth plan rests on being first to market with complex generics and on buying branded products that fit its distribution. The clearest example is semaglutide. In May 2026 Health Canada approved Apo-Semaglutide, a generic of Novo Nordisk’s Ozempic, the first such approval for a Canadian-based company, and in June Apotex launched Sevmia, a generic of Wegovy, first to market in Canada. In the United States, where patents run until 2032, the FDA gave tentative approval in April 2026 for a generic Ozempic that cannot launch until then.

Other 2026 launches include generic sitagliptin and sitagliptin-metformin in the United States with 180 days of shared exclusivity, four Infuvite injectable products for the US hospital market, and Iheezo, a branded ophthalmic anaesthetic, in Canada. The brands and biosimilars line, now C$161 million a quarter, was strengthened in July 2026 when Apotex completed its acquisition of Cumberland Pharmaceuticals of Nashville for C$141.8 million (US$100 million), adding Kristalose, Caldolor, Sancuso, Vibativ and other hospital brands.

Manufacturing is the other lever. Apotex reports capacity of 25 billion doses and in April 2026 invested with Halo Pharmaceutical, an SK Capital portfolio company, in a sterile filling facility in New Jersey, giving it injectable capacity in the United States at a time when tariff threats make domestic US production more valuable. For a Canadian manufacturer selling into the United States, the 2025 trade war and tariff dispute is a live risk, although pharmaceuticals have so far been largely exempt under CUSMA.

How does Canada’s drug-pricing regime work, and who does it favour?

Canada regulates drug prices at three levels, and each affects generics differently. The Patented Medicine Prices Review Board, a federal body, sets ceiling prices for patented medicines by reference to a basket of comparator countries; a 2022 reform dropped the United States and Switzerland from that basket, lowering ceilings, though further proposed changes were withdrawn after industry litigation. The PMPRB does not regulate generics directly, but lower brand ceilings compress the price from which generic discounts are calculated.

The pan-Canadian Pharmaceutical Alliance, through which provinces and territories negotiate jointly, sets generic prices as a percentage of the brand price under a framework with the Canadian Generic Pharmaceutical Association. The current tiered framework, extended in recent years, prices most multi-source generics at a fraction of the brand price, with lower percentages for the highest-volume molecules. For a company like Apotex, which supplies a large share of those molecules, this means predictable but thin unit pricing, offset by scale.

Public drug coverage itself is fragmented across provincial plans, which is what the Pharmacare Act, passed in October 2024, is meant to change. The Act commits Ottawa to work toward universal single-payer coverage, starting with diabetes medicines and contraceptives through bilateral agreements with provinces; by 2026 several provinces had signed. For generic suppliers, single-payer coverage usually means higher volume and lower prices, which suits the largest, lowest-cost manufacturer. Apotex’s strong Canadian growth in 2026 partly reflects that dynamic.

What are the risks for Apotex as a public company?

The first risk is US price erosion. Apotex’s US revenue excluding the Revlimid product fell 8.6 per cent in the latest quarter, and the US generics market has seen years of consolidation among buyers that pushes prices down. The Cumberland brands and the sterile injectables investment are responses, but the United States remains a market where Apotex is a mid-sized player rather than a leader.

The second is regulatory and legal. Apotex has a long history of FDA compliance actions and antitrust settlements, and a company whose strategy is to launch at risk will always face damages claims when it loses. Section 8 of Canada’s patented medicines regulations lets a generic claim damages when it is wrongly kept off the market, but the reverse also applies, and judgments can run to hundreds of millions.

The third is ownership. SK Capital’s September 2026 secondary offering shows it will sell down, which creates share overhang, and the company’s C$1.25 billion of new bonds plus the remaining term debt mean leverage is reduced rather than eliminated. Public investors who bought at C$24 are relying on fiscal 2027 guidance of upper-mid-single-digit growth and 30 per cent margins; a shortfall in either, especially in Canada, would be punished.

What can founders and investors learn from Apotex?

The first lesson is that a litigation strategy can be a competitive strategy. Sherman understood that in a regulated industry the rules of market entry are themselves contestable, and he built a legal department that treated patent challenges as routine operations rather than crises. Companies in regulated sectors, from fintech challengers facing bank regulation to energy developers, can learn from the discipline of filing early and litigating consistently.

The second lesson concerns succession. Apotex was run by its founder for 43 years with no public successor, and when he died suddenly the company spent five years in a holding pattern before a sale to private equity and a further three before a listing. A founder-owned business of C$2.5 billion in revenue without a succession plan is a risk to its employees, customers and heirs, however strong its operations; the Sherman estate litigation showed how quickly a family’s affairs can become public.

The third lesson is about capital structure and the public markets. Private equity used Apotex’s listing to cut debt by C$800 million in one transaction and to earn an investment-grade rating within six weeks, which is the opposite of the path Bausch Health has been on for a decade. Together with AbCellera’s cash discipline, Apotex shows that Canadian life-sciences companies can access capital on reasonable terms when their earnings are visible and their leverage is falling. Readers interested in how a Toronto-listed health company compares with its peers in other markets can start with the Toronto entry in the City Startup Atlas.

Frequently Asked Questions